CROMOS™ PHARMA FOUNDED
Cromos™ Pharma was founded in 2004 in Portland, Oregon, USA.
OFFICE IN RUSSIA (MOSCOW)
Cromos™ Pharma office opened in Moscow, Russia.
OPERATIONS IN UKRAINE
Soon after beginning operations in Russia, Cromos™ Pharma added operations in Ukraine.
OFFICE IN UKRAINE
After two years of successful growth of operations in Ukraine Cromos™ Pharma opened an office and registered a local legal entity.
OPERATIONS IN LITHUANIA
Cromos™ Pharma continued to strengthen its market presence by starting activities in Lithuania.
OPERATIONS IN LATVIA
Cromos™ Pharma started operations in Latvia with initiation of studies in dermatology.
SECOND OFFICE IN RUSSIA (SMOLENSK)
After several steady years of expansion the second office in Russia in the city of Smolensk was established.
OPERATIONS IN ESTONIA
Cromos™ Pharma started operations in Estonia by successfully participating in an international multi-centre study in chronic heart failure.
OPERATIONS IN BELARUS
Cromos™ Pharma continued to expand its geography and started operations in Belarus with a successful international multi-centre trial in patients with angina pectoris.
Read more
EU HQ ESTABLISHED IN IRELAND
Cromos™ Pharma's EU Headquarters established in Dublin, Ireland, as part of the company's further growth strategy in EU market.
OFFICE IN GEORGIA
Cromos™ Pharma opened an office in the capital city of Tbilisi and started to provide full service support for clinical trials in Georgia.
Read more
OPERATIONS IN MOLDOVA
Cromos™ Pharma initiated operations in Moldova.
OPERATIONS IN ISRAEL
Initiation of operations in Israel allow Cromos™ Pharma to expand its capabilities in running cutting-edge pharmaceutical and medical device trials.
Read more
OPERATIONS IN BULGARIA
Continuing Cromos™ Pharma's strategy for geographical expansion, operations in Bulgaria were started with an arterial hypertension trial.
OPERATIONS IN SLOVAKIA
Including Slovak sites into an international phase III study in NSCLC marked the beginning of Cromos™ Pharma's high grade operations in this country.
OPERATIONS IN CZECH REPUBLIC
Cromos™ Pharma announced the launch of operations in Czech Republic.
OPERATIONS IN ROMANIA
Cromos™ Pharma's European presence expanded further with the starting of operations in Romania.
OFFICE IN CZECH REPUBLIC
Successful initiation of two studies in Czech Republic led to the opening of an office in Prague.
Read more
OPERATIONS IN POLAND
The start of operations in Poland allowed Cromos™ Pharma to enter one of the most prominent Eastern European clinical trials markets.
LAUNCH OF REFERRAL SITE NETWORK
By analyzing study population, sites’ motivation to enroll, type of disease, subjects’ barriers to participation in the studies, we developed a comprehensive system of recruitment optimization.
Read more
OFFICE IN HUNGARY
Further geographic expansion included opening a representative office in Budapest, Hungary.
Read more
OPERATIONS IN ARMENIA
Cromos™ Pharma started to provide clinical trials services in Armenia, an unsaturated area for clinical research.
OPERATIONS IN KAZAKHSTAN
Cromos™ Pharma launched its first clinical trial in Kazakhstan, an emerging clinical trial destination in Central Asia.
Read more
OPERATIONS IN NORTH AMERICA
With a new clinical operations base in South Florida, Cromos™ Pharma is poised to better serve US and international clients who seek FDA approval and access to North, Central and South America.
OFFICE IN POLAND
The opening of the new office strengthened Cromos Pharma’s position in Poland where it has been operational since 2015.
CLINICAL TRIALS DURING COVID-19
The COVID-19 pandemic dominated 2020. Cromos Pharma was proud to play its part in the fight against the virus by managing its first major global clinical trial of a drug developed by a Sponsor to treat severe COVID-19 infection. Throughout 2020, Cromos Pharma continued to manage successful clinical trials related to COVID-19 as well as a wide-range of other therapeutic areas.
10,000 PATIENTS ENROLLED IN ONCOLOGY STUDIES
In 2021, Cromos Pharma achieved an important milestone as it reached 10,000 patients enrolled in its oncological studies. Cromos Pharma also managed its first trial investigating a vaccine for COVID-19.
